Answers are grounded in this paper and cite their sources.
Cross-platform analysis reveals variability in amyloid PET Z-scores in patients with cognitive impairment, suggesting careful interpretation.
There was overall concordance between Syngo.Via and MIMneuro quantitative amyloid PET analysis software packages, however with significant region- and amyloid burden-dependent variability that increased in the intermediate-centiloid group. These differences may influence interpretation and determination of treatment eligibility in borderline cases, emphasizing that Z-scores from different commercial platforms should not be used interchangeably without cross-validation.
No takes yet. Share an insight, caveat, or question.
Ebani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: